Selank vs Kpv
Which Is Right for You? Complete Comparison (2026)
Selank vs KPV comparison — tuftsin-derived anxiolytic that modulates GABA and IL-6 for anxiety and stress vs alpha-MSH fragment KPV that targets NF-kB.
Selank vs Kpv: At a Glance
- ✓Synthetic tuftsin analogue — heptapeptide anxiolytic
- ✓Approved in Russia for generalized anxiety and neurasthenia
- ✓Modulates GABA, serotonin, and dopamine systems
- ✓Immunomodulatory — enhances IL-6 and affects T-cell function
- ✓Administered intranasally — no sedation or dependence risk
- ✓C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH
- ✓Potent anti-inflammatory — suppresses NF-kB signaling
- ✓Reduces TNF-alpha, IL-6, and other inflammatory cytokines
- ✓No melanogenic (tanning) effect unlike full alpha-MSH
- ✓Being studied for IBD, dermatitis, and mucosal inflammation
Detailed Comparison
| Feature | Selank | Kpv |
|---|---|---|
| Mechanism | Synthetic tuftsin analogue | Anti-inflammatory tripeptideBest |
| Dosing | 250-500 mcg intranasally daily | 200-500 mcg SC or oral daily |
| Administration | Intranasal | Subcutaneous or oral |
| Half-life | Minutes in plasma; prolonged CNS effects | Short — typical for small peptides |
| FDA Status | Not FDA-approved (approved in Russia) | Not FDA-approved — research peptide |
| Key Trial | Zozulya AA et al. Bull Exp Biol Med 2001 — anxiolytic activity | Brzoska T et al. Endocr Rev 2008 — alpha-MSH anti-inflammatory review |
| Side Effects | Nasal irritation; no significant adverse effects reported | Limited data; generally well-tolerated in studies |
Which Should You Choose?
Selank (synthetic tuftsin analogue) and KPV (alpha-MSH tripeptide) (anti-inflammatory tripeptide) serve different clinical roles despite both being in the Anxiolytic peptide space. Selank synthetic heptapeptide analogue of tuftsin with anxiolytic and immunomodulatory properties. KPV (alpha-MSH tripeptide) c-terminal tripeptide fragment of alpha-msh with potent anti-inflammatory effects.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Selank and Kpv
Choosing between Selank and Kpv depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Selank and Kpv is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Selank vs Kpv: Frequently Asked Questions
Selank is a synthetic tuftsin analogue while KPV (alpha-MSH tripeptide) is a anti-inflammatory tripeptide. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Selank works as a synthetic tuftsin analogue (250-500 mcg intranasally daily), while KPV (alpha-MSH tripeptide) is a anti-inflammatory tripeptide (200-500 mcg SC or oral daily). They have different half-lives (Minutes in plasma; prolonged CNS effects vs Short — typical for small peptides), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Selank or Kpv in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.